Consano Bio
June 22, 2026
Theater 1
Type: Company Presentation
Focus Area:
Regenerative Medicine
Consano Bio is a clinical stage Biotech developing a first in class allogenic, platelet and plasma derived biologic for the treatment of chronic lumbosacral radiculopathy. C-1101, the companies first clinical asset, is a potential disease modifying biologic, locally delivered to the spinal nerve to induce inflammatory modulation and localized cell proliferation.
The phase I study (USA and Australian patients) is evaluating safety and efficacy measures and will report in 1H 2027
Company HQ City:
Burlington,
Company HQ State:
MA
Company HQ Country:
United States
Year Founded:
2023
Lead Product in Development:
C-1101
CEO
Andrew Hall
Development Phase of Lead Product
Phase I
Number of Unlicensed Products Looking for Licensing
2
When you expect your next catalyst update?
1H 2027
What is your next catalyst (value inflection) update?
Phase I data
Primary Speaker
)
)
)
){kind=logo}
){kind=logo}
)
)
){kind=logo}
){kind=logo}